SIRT6 variants from centenarians lower senescent cell burden in aging tissues

SIRT6 variants enriched in centenarian populations function as cellular safeguards against accelerated aging, according to researchers who introduced these mutations into human embryonic stem cells to study their effects in native genomic context. Centenarians carrying these variants produce elevated SIRT6 protein and exhibit altered enzymatic activity: enhanced mono-ADP-ribosyltransferase function paired with reduced deacetylase activity, which delays replicative senescence and confers resistance to progeria-induced stress. In differentiated cell lineages, these variants preserved DNA repair gene expression programs while suppressing transposable element derepression—the twin drivers of accumulated damage. The team demonstrated that AAV-mediated delivery of centenarian SIRT6 and pharmacological activation via fucoidan from Fucus vesiculosus partially reversed aging-associated molecular defects, including genome instability and LINE1 derepression. For the longevity-conscious reader, the implication is strategic: rather than pursuing genetic replication of centenarian SIRT6, resources should prioritize development of potent senolytics that selectively clear senescent cells from aged tissues on an ongoing basis—an intervention with substantially greater therapeutic reach than genetic modification alone.